News coverage about Express Scripts Holding (NASDAQ:ESRX) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Express Scripts Holding earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.39685407968 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Toronto Dominion Bank Sold A Lot More Express Scripts Holding Company (ESRX) Stock Last Quarter – Modern Readers (modernreaders.com)
- Remicade Is a Litmus Test for PBMs (finance.yahoo.com)
- Express Scripts Holding Company (ESRX) Stake Decreased by Shell Asset Management Co (vothemes.com)
- 3 Healthcare Stocks That Are Looking Cheap Right Now – Madison.com (host.madison.com)
- Zooming in on the Numbers for Express Scripts Holding Company (NASDAQ:ESRX) – Jonesboro Recorder (jonesbororecorder.com)
Express Scripts Holding (NASDAQ ESRX) traded down 0.79% during midday trading on Friday, reaching $60.56. 2,382,740 shares of the company’s stock were exchanged. The company has a market cap of $34.98 billion, a price-to-earnings ratio of 10.51 and a beta of 0.90. The firm has a 50-day moving average price of $62.23 and a 200 day moving average price of $64.20. Express Scripts Holding has a 12-month low of $57.80 and a 12-month high of $77.61.
A number of brokerages recently commented on ESRX. UBS AG set a $71.00 price target on shares of Express Scripts Holding and gave the company a “hold” rating in a research note on Tuesday, April 25th. Bank of America Corporation restated a “neutral” rating and set a $77.00 target price on shares of Express Scripts Holding in a research report on Tuesday, April 25th. Cowen and Company decreased their target price on shares of Express Scripts Holding from $90.00 to $83.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 25th. SunTrust Banks, Inc. restated a “buy” rating on shares of Express Scripts Holding in a research report on Tuesday, April 25th. Finally, Mizuho decreased their target price on shares of Express Scripts Holding from $76.00 to $61.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 25th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $71.17.
Express Scripts Holding Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
What are top analysts saying about Express Scripts Holding Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Express Scripts Holding Company and related companies.